ULMAYSA Trademark

Trademark Overview


On Monday, June 2, 2025, a trademark application was filed for ULMAYSA with the United States Patent and Trademark Office. The USPTO has given the ULMAYSA trademark a serial number of 99213507. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Thursday, January 8, 2026. This trademark is owned by H. Lundbeck A/S. The ULMAYSA trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Medical apparatus, namely, infusion and injection devices for administering drugs; medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, medical syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for medicines also containing downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; medical devices and instruments for the diagnosis, administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems for use with downloadable computer software comprised of medical instrum...

Sanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior synd...
ulmaysa

General Information


Serial Number99213507
Word MarkULMAYSA
Filing DateMonday, June 2, 2025
Status680 - APPROVED FOR PUBLICATION
Status DateThursday, January 8, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical apparatus, namely, infusion and injection devices for administering drugs; medical syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, medical syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for medicines also containing downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; medical devices and instruments for the diagnosis, administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems for use with downloadable computer software comprised of medical instruments and recorded software sold in connection therewith for information and information management for use of a web-based physical and psychological and neurological examination and assessment of patients and clients; integrated medical systems comprised of medical devices and instruments for treating central nervous system diseases and disorders and psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases, all for the purposes of management, measurement, monitoring, evaluation, control, collection, storage, transmission and examination of patient and client data and information; medical instruments for providing medication administering information, guidance, management in the nature of devices for delivery and administering of medicines and infusion pumps
Goods and ServicesSanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington's disease, insomnia, Parkinson's disease, sclerosis, multiple sclerosis, schizophrenia, bipolar disorder, cancer, pain, migraine, headache, Horton's headache, traumatic brain injury, post-traumatic brain injury, dizziness, seizures, stroke, cognitive impairment, cognitive disorders and diseases, mood disorders, falls, movement disorders and diseases, tremor, agitation, mania, aggression, autism, melancholia, Obsessive Compulsive Disorder (OCD), Tourette's syndrome, restlessness, akathisia, fatigue, somnolence, nausea, Cushing's disease, Adrenogenital syndrome (AGS), narcolepsy, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Progressive Supranuclear Palsy (PSP), Thyroid Associated Orbitopathy (TAO), Graves Orbitopathy, Hashimoto's Thyroiditis, alcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposes, namely, chemical reagents for medical use, diagnostic chemical reagents for medical purposes; medical diagnostic reagents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 2, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, June 2, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameH. Lundbeck A/S
Party Type10 - Original Applicant
Legal Entity Type65 - NOT AVAILABLE
AddressValby 2500
DK

Trademark Events


Event DateEvent Description
Monday, June 2, 2025NEW APPLICATION ENTERED
Monday, June 2, 2025APPLICATION FILING RECEIPT MAILED
Wednesday, October 8, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 9, 2025ASSIGNED TO EXAMINER
Wednesday, October 15, 2025NON-FINAL ACTION WRITTEN
Wednesday, October 15, 2025NON-FINAL ACTION E-MAILED
Wednesday, October 15, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 16, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 16, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 16, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 2, 2026FINAL REFUSAL WRITTEN
Friday, January 2, 2026FINAL REFUSAL E-MAILED
Friday, January 2, 2026NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, January 8, 2026EXAMINERS AMENDMENT -WRITTEN
Thursday, January 8, 2026EXAMINERS AMENDMENT E-MAILED
Thursday, January 8, 2026NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, January 8, 2026EXAMINER'S AMENDMENT ENTERED
Thursday, January 8, 2026APPROVED FOR PUB - PRINCIPAL REGISTER